Sustained Release Excipients Market Report 2026

Sustained Release Excipients Market Overview

• Sustained Release Excipients market size has reached to $1.51 billion in 2025 • Expected to grow to $2.3 billion in 2030 at a compound annual growth rate (CAGR) of 8.9% • Growth Driver: Surge In Demand For Personalized Medicine Drives Growth In The Sustained-Release Excipients Market • Market Trend: Innovations In Spray Drying Technology Enhance Production Capacity And Support Sustained Release Formulations • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Sustained Release Excipients Market?

Sustained-release excipients refer to pharmaceutical ingredients or additives used in the formulation of drug delivery systems designed to achieve controlled or sustained release of active pharmaceutical ingredients (APIs) over an extended period of time. These excipients play a crucial role in controlling the release rate and duration of drug action, thereby optimizing therapeutic efficacy and patient compliance. The main types of sustained-release excipient products are gelatin, polymers, minerals, sugars, alcohol, and chitosan. Gelatin refers to a protein derived from collagen, which is the most abundant protein in animal connective tissues such as skin, bones, and tendons. These are administered through various routes, including oral, intramuscular, subcutaneous, transdermal, vaginal, ophthalmic, intravenous, and others. Several types of technologies are involved, such as targeted delivery, microencapsulation, the Wurster technique, transdermal, implants, and coacervation.

What Is The Sustained Release Excipients Market Growth Forecast?

The sustained release excipients market size is expected to see strong growth in the next few years. It will grow to $2.3 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to rising demand for long acting injectables, growth in biologics and specialty drugs, increasing investment in drug delivery R&D, demand for patient centric formulations, expansion of pharmaceutical manufacturing in emerging markets. Major trends in the forecast period include rising demand for controlled drug delivery systems, growing use of polymers in sustained release formulations, increasing adoption of oral sustained release dosage forms, expansion of microencapsulation and coacervation technologies, focus on patient compliance and reduced dosing frequency.

What Is The Driver Of The Sustained Release Excipients Market?

The growing demand for personalized medicine is expected to propel the growth of the sustained-release excipients market going forward. Personalized medicine, or personalized care, refers to the method by which medical professionals study patients' unique genes, proteins, and other bodily components to provide and organize customized care using precision medicine. Sustained-release excipients play a crucial role in personalized medicine by enabling the development of drug formulations tailored to individual patient needs. For instance, in February 2024, according to the Personalised Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from 6 in 2022. Therefore, the growing demand for personalized medicine is driving the growth of the sustained-release excipients market.

Key Players In The Global Sustained Release Excipients Market

Major companies operating in the sustained release excipients market are BASF SE, Ashland Global Holdings Inc, Colorcon Inc, Evonik Industries AG, Lubrizol Corporation, Merck KGaA, Roquette Freres, Shin Etsu Chemical Co Ltd, JRS Pharma GmbH Co KG, SPI Pharma Inc, Croda International Plc, Lonza Group AG, Chemische Fabrik Budenheim KG, Asahi Kasei Corporation, DuPont de Nemours Inc, Dow Chemical Company, Eastman Chemical Company, Gattefosse SAS, Balchem Corporation, Associated British Foods plc, Ransom Naturals Ltd, Cellulose Solutions Private Limited

Global Sustained Release Excipients Market Trends and Insights

Major companies operating in the sustained release excipients market are focusing on developing advanced solutions, such as multifunctional polymer platforms, to enhance drug formulation efficiency, reduce delivery time, and support controlled-release profiles. Multifunctional polymer platforms refer to excipients that enable immediate, delayed, and sustained drug release while being compatible with formulation technologies like hot melt extrusion and solubility-enhancing spray drying. For instance, in September 2024, Evonik, a Germany-based company, started operations of a new spray drying facility at its Darmstadt site for EUDRAGIT polymers. The facility increases production capacity, reduces delivery times, and integrates fully with existing production networks. It uses green electricity and steam from local waste incineration to lower CO2 emissions by over 1,000 tons annually. Operating under IPEC-GMP pharmaceutical guidelines and directly connected to the production of aqueous dispersions, the facility minimizes transportation and streamlines the supply chain. The polymers produced support immediate, delayed, and sustained release formulations, strengthening Evonik’s global hub for oral drug delivery solutions and reinforcing its ability to support innovative pharmaceutical development efficiently.

What Are Latest Mergers And Acquisitions In The Sustained Release Excipients Market?

In March 2024, Roquette, a France-based provider of pharmaceutical excipients, acquired IFF Pharma Solutions for an undisclosed amount. The acquisition aims to strengthen Roquette's position in the pharmaceutical excipients market. IFF Pharma Solutions is a US-based company that manufactures sustained-release excipients, which are specialized ingredients used in pharmaceutical formulations to control the release rate of active pharmaceutical ingredients (APIs).

What Defines the Sustained Release Excipients Market?

The sustained-release excipients market consists of sales of ethyl cellulose, lipid-based excipients, waxes, fatty acids, polyethylene glycol (PEG), copovidone, and osmotic agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Sustained Release Excipients Market Report 2026?

The sustained release excipients market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sustained release excipients industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.